FTSE MIB
33.799,87 +53,21 (+0,16%) Dow Jones
38.124,98 +221,69 (+0,58%) Nasdaq
15.742,05 +136,57 (+0,88%) Nikkei 225
38.236,07 -37,98 (-0,10%) Petrolio
78,93 -0,07 (-0,09%) Bitcoin EUR
54.885,18 +992,48 (+1,84%)
Immutep Limited (IMM.AX)
| Chiusura precedente | 0,4200 |
| Aperto | 0,4200 |
| Denaro | 0,4150 x 3068000 |
| Lettera | 0,4200 x 2473100 |
| Min-Max giorno | 0,4050 - 0,4300 |
| Intervallo di 52 settimane | 0,2215 - 0,4550 |
| Volume | |
| Media Volume | 1.734.827 |
| Capitalizzazione | 499,309M |
| Beta (5 anni mensile) | 1,83 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,0400 |
| Prossima data utili | 28 lug 2024 - 01 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 0,94 |
GlobeNewswireImmutep Announces Publication of Abstracts at ESMO Congress 2023
Media Release New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CESTImmutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM ET) SYDNEY, AUSTRALIA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immuno
- GlobeNewswire
Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
Media Release SYDNEY, AUSTRALIA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announces an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, taking place in San Diego, California and virtually from 1 to 5 November 2023. Presentation DetailsTitle: Biomarke
- GlobeNewswire
Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use
Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achievedMedia Release SYDNEY, AUSTRALIA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the regulatory authorization of eftilagimod alpha (“efti”) manufactured at commercial 2,000L scale for use in clinical trials across multiple Euro
